Medicenna Reports MDNA209 Preclinical Survival Results in Autoimmune Models
The company said its engineered Superkine blocked CD122 and extended median survival by up to fourfold in aggressive mouse models. It is designed to inhibit IL-2 and IL-15 signalling.